Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
10 studies found for:    "Charcot-Marie-Tooth disease type 1A"
Show Display Options
Rank Status Study
1 Not yet recruiting Tools for Therapeutic Evaluation in Charcot-Marie-Tooth Disease Type 1A: Outcome Measures and Biomarkers
Condition: Charcot-Marie-Tooth Disease Type 1A
Interventions: Other: Clinical evaluation;   Other: electrophysiological record;   Other: Muscle MRI;   Other: blood samples analysis
2 Recruiting Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
Condition: Charcot-Marie-Tooth Disease Type 1A
Interventions: Drug: PXT3003 dose 1;   Drug: PXT3003 dose 2;   Drug: placebo
3 Unknown  Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program for Charcot−Marie−Tooth Neuropathy Type 1A (CMT1A)
Conditions: Charcot-Marie-Tooth Disease;   Charcot-Marie-Tooth Disease Type 1A
Interventions: Other: TreSPE;   Other: SPE
4 Recruiting Driving Ability in Patients With CMT 1A
Condition: CMT 1A
Intervention: Device: UIHC Driving Simulator
5 Unknown  Correlation Between Clinical and Electrophysiological Phenotypes in a Population of Patients With Neuropathy Charcot-Marie-Tooth Disease Type 1A
Condition: Charcot-Marie-Tooth Type 1A Neuropathy
Intervention:
6 Completed High Dose Ascorbic Acid Treatment of CMT1A
Condition: Charcot-Marie-Tooth Disease, Type Ia
Interventions: Drug: Ascorbic acid (Vitamin C);   Drug: placebo
7 Completed Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A
Conditions: Charcot-Marie-Tooth Disease;   Hereditary Neuropathy With Liability to Pressure Palsies;   Genetic Disorders;   Tooth Disorders
Interventions: Drug: PXT3003;   Other: Placebo
8 Recruiting Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2
Conditions: Charcot-Marie-Tooth Disease, Type Ia (Disorder);   HMSN
Intervention:
9 Not yet recruiting Ulipristal Acetate In Disease Charcot-Marie-Tooth Type of 1A
Condition: CMT1A
Interventions: Drug: EllaOne;   Drug: EllaOne placebo
10 Completed Ascorbic Acid Treatment in CMT1A Trial (AATIC)
Conditions: Charcot-Marie-Tooth Disease;   Hereditary Motor and Sensory Neuropathies
Interventions: Drug: Placebo;   Drug: ascorbic acid

Indicates status has not been verified in more than two years